Class effects of SGLT2 inhibitors on cardiorenal outcomes. [electronic resource]
Producer: 20200504Description: 99 p. digitalISSN:- 1475-2840
- Benzhydryl Compounds -- adverse effects
- Canagliflozin -- adverse effects
- Cardiovascular Diseases -- drug therapy
- Cardiovascular System -- drug effects
- Diabetes Mellitus, Type 2 -- drug therapy
- Diabetic Nephropathies -- drug therapy
- Disease Progression
- Glucosides -- adverse effects
- Humans
- Kidney -- drug effects
- Protective Factors
- Randomized Controlled Trials as Topic
- Renal Insufficiency, Chronic -- drug therapy
- Risk Assessment
- Risk Factors
- Sodium-Glucose Transporter 2 Inhibitors -- adverse effects
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
There are no comments on this title.
Log in to your account to post a comment.